Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS Era

20 Dec 2024

Abstract excerpt

Liquid biopsy (LB) involves the analysis of circulating tumour-derived DNA (ctDNA), providing a minimally invasive method for gathering both quantitative and qualitative information. Genomic analysis of ctDNA through next-generation sequencing (NGS) enables comprehensive genetic profiling of tumours, including non-driver alterations that offer prognostic insights. LB can be applied in both early-stage disease...

Topics

Join the communities discussing this publication.

Cancer Genomics and Diagnostics
Lung Cancer Diagnosis and Treatment
Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39769431
DOI: 10.3390/ijms252413669

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Role of ctDNA in the Management of Non-Small-Cell Lung Cancer in the AI and NGS EraPMID 39769431Read ↗

Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directionsSemantic proximity Read ↗

Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challengesSemantic proximity Read ↗

Genomics and the early diagnosis of lung cancerSemantic proximity Read ↗

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

Exploring AI tools and multi-omics for precision medicine in lung cancer therapy.Semantic proximity Read ↗

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancerSemantic proximity Read ↗

Monitoring Somatic Genetic Alterations in Circulating Cell-Free DNA/RNA of Patients with "Oncogene-Addicted" Advanced Lung Adenocarcinoma: A Real-World Clinical Study.Semantic proximity Read ↗

Recommendations for reporting tissue and circulating tumour (ct)DNA next-generation sequencing results in non-small cell lung cancerSemantic proximity Read ↗

Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.Semantic proximity Read ↗

Clinical Utility of ctDNA Analysis in Lung Cancer—A ReviewSemantic proximity Read ↗

Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.